In this study, the relatively low rate of tumor proliferation control by SSA may have been found because 66.7% of the patients had pathological features with Ki-67% ≥ 10% at baseline, which might have a poor response to SSA, as in previous reports. The gene discussed is MKI67; the disease is neoplasm.